60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.310
-0.040 (-2.96%)
At close: Aug 14, 2025, 4:00 PM
1.280
-0.030 (-2.29%)
After-hours: Aug 14, 2025, 4:54 PM EDT
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $307.87K in the quarter ending June 30, 2025, with 144.93% growth. This brings the company's revenue in the last twelve months to $984.49K, up 128.70% year-over-year. In the year 2024, 60 Degrees Pharmaceuticals had annual revenue of $681.35K with 168.70% growth.
Revenue (ttm)
$984.49K
Revenue Growth
+128.70%
P/S Ratio
1.44
Revenue / Employee
$328,165
Employees
3
Market Cap
4.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | 2.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SXTP News
- 1 day ago - 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format - GlobeNewsWire
- 2 months ago - Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results - GlobeNewsWire
- 4 months ago - Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey - GlobeNewsWire